<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a case of spontaneously reversible refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo>, a subtype of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 secondary to <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (AZA) in a young renal transplant recipient </plain></SENT>
<SENT sid="1" pm="."><plain>AZA was stopped after that conventional cytogenetics and fluorescence in situ hybridization (FISH) had demonstrated the existence of a <z:mp ids='MP_0004026'>monosomy</z:mp> 7 clone, 4 months later, haematological values had considerably improved and the karyotypic examination as well as the FISH analysis were <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>The spontaneous remission of this <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:mp ids='MP_0004026'>monosomy</z:mp> 7, which is usually associated with a particularly poor prognosis, could be due to the recovery of a better immunosurveillance following the withdrawal of AZA </plain></SENT>
</text></document>